BioAtla, Inc.
- Close
- Oct 22, 2026
- Market cap
- $2.05M
- 1.66M shares
- Filings
- 510
Q3 2023
—Q2 2026N/M FY25 yoy
Q2 2026N/M FY25 yoy
—
—
—Q2 2026N/M FY25 yoy
Q2 2026−85.5% FY25 yoy
- $2.05M
- —
- —
- —
- —
- —
FY2025 figures · derived
Price
Oct 22, 2026 · Official close
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2021 | 2021-12-31 | $300,000 | reported |
Biological products, except diagnostic substances
BioAtla, Inc. is the 162nd largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
PMCBPharmaCyte Biotech, Inc.$0.0——$3.3MVIVSVivoSim Labs, INC.$131.0K9.0%10,567.2%$2.8M
BCABBioAtla, Inc. (this company)———$2.1M
AGTXAgentix Corp.———$2.0MSLXNSilexion Therapeutics Corp———$1.7MCLDICalidi Biotherapeutics, Inc.———$1.7MSCNIScinai Immunotherapeutics Ltd.$1.3M99.2%633.6%$1.6MCRISCuris Inc$9.4M13.4%80.3%$1.2MABPOAbpro Holdings, Inc.———$1.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
BioAtla, Inc. · CIK 1826892 · Engraved from SEC EDGAR